Medicine and Dentistry
Adverse Event
16%
Anticoagulation
10%
Antidiabetic Agent
10%
Behcet Disease
21%
Blood Glucose
16%
Body Weight
10%
Carbohydrate Counting
21%
Cardiac Magnetic Resonance Imaging
10%
Cardiovascular Risk
5%
Clinical Study
10%
Clinical Trial
7%
Diabetes
94%
Diabetes Mellitus
45%
Diabetic Ketoacidosis
26%
Diagnosis
21%
Diseases
6%
Glucagon-Like Peptide-1 Agonist
26%
Glycemic
21%
Glycemic Control
23%
Heart Tumor
21%
Hemoglobin A1c
35%
Hyperglycemia
10%
Hypoglycemia
47%
Immunosuppressive Treatment
10%
Infection
10%
Insulin Degludec Plus Liraglutide
21%
Insulin Dependent Diabetes Mellitus
53%
Insulin Infusion
21%
Insulin Pump
26%
Insulin Treatment
10%
Intracardiac Thrombosis
10%
Maturity Onset Diabetes of the Young
29%
Meta-Analysis
25%
Metabolic Disorder
14%
Mortality Rate
10%
Observational Study
25%
Patient with Diabetes
21%
Patient with Type 1 Diabetes
21%
Perinatal Death
5%
Population Research
10%
Prevalence
10%
Quality of Life
7%
Randomized Clinical Trial
21%
Retrospective Cohort Study
10%
Retrospective Study
16%
Right Atrium
10%
Semaglutide
21%
Sodium Glucose Cotransporter 2 Inhibitor
21%
Systematic Review
47%
Thrombus
21%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
31%
Antidiabetic Agent
9%
Cardiovascular Risk
5%
Clinical Study
17%
Clinical Trial
5%
Cohort Study
10%
Congenital Malformation
5%
Creatinine
10%
Diabetes Mellitus
57%
Diabetic Ketoacidosis
26%
Disease Duration
5%
Diseases
22%
Glucagon
7%
Glucagon Like Peptide 1 Receptor Agonist
29%
Glucagon-Like Peptide-1
14%
Glycosylated Hemoglobin
13%
Hemoglobin A1c
78%
Hypoglycemia
45%
Infection
10%
Insulin Degludec
21%
Insulin Degludec Plus Liraglutide
42%
Insulin Dependent Diabetes Mellitus
42%
Ketoacidosis
5%
Liraglutide
21%
Macrosomia
5%
Maternal Hypertension
5%
Mortality Rate
10%
Non Insulin Dependent Diabetes Mellitus
100%
Observational Study
25%
Perinatal Death
5%
Population Study
10%
Preeclampsia
5%
Premature Labor
5%
Prevalence
17%
Receptor Agonist
7%
Retrospective Study
5%
Semaglutide
42%
Sodium Glucose Cotransporter 2 Inhibitor
21%
Nursing and Health Professions
Adverse Event
10%
Antidiabetic Agent
10%
Body Weight
7%
Clinical Outcome
21%
Clinical Practice
10%
Glucagon Like Peptide 1 Receptor Agonist
21%
Glucose Blood Level
10%
Hemoglobin A1c
32%
Hypoglycemia
35%
Insulin Degludec Plus Liraglutide
21%
Insulin Dependent Diabetes Mellitus
32%
Insulin Pump
21%
Insulin Treatment
10%
Lipid Blood Level
10%
Literature Review
21%
Meta Analysis
21%
Non Insulin Dependent Diabetes Mellitus
14%
Nutrition Assessment
7%
Patient with Diabetes
21%
Patient with Type 1 Diabetes
21%
Quality of Life
10%
Sodium Glucose Cotransporter 2 Inhibitor
21%
Systematic Review
32%
